TY - JOUR
T1 - Diabetic macular edema
T2 - Current and emerging therapies
AU - Wenick, Adam
AU - Bressler, Neil
PY - 2012/1
Y1 - 2012/1
N2 - Diabetic macular edema is a leading cause of vision impairment among people within the working-age population. This review discusses the pathogenesis of diabetic macular edema and the treatment options currently available for the treatment of diabetic macular edema, including for focal/grid photocoagulation, intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents. The biologic rationale for novel therapeutic agents, many of which are currently being evaluated in clinical trials, also is reviewed.
AB - Diabetic macular edema is a leading cause of vision impairment among people within the working-age population. This review discusses the pathogenesis of diabetic macular edema and the treatment options currently available for the treatment of diabetic macular edema, including for focal/grid photocoagulation, intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents. The biologic rationale for novel therapeutic agents, many of which are currently being evaluated in clinical trials, also is reviewed.
KW - Diabetic Macular Edema
KW - Focal/Grid Photocoagulation
KW - Intravitreal Corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=84856381241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856381241&partnerID=8YFLogxK
U2 - 10.4103/0974-9233.92110
DO - 10.4103/0974-9233.92110
M3 - Review article
C2 - 22346109
AN - SCOPUS:84856381241
SN - 0974-9233
VL - 19
SP - 4
EP - 12
JO - Middle East African Journal of Ophthalmology
JF - Middle East African Journal of Ophthalmology
IS - 1
ER -